Vaxcyte Inc reports results for the quarter ended September 30 - Earnings Summary

• Vaxcyte Inc PCVX.OQ reported a quarterly adjusted loss of $1.56​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of ten analysts for the quarter was for a loss of $1.27 per share. Wall Street expected results to range from $-1.60 to -100 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Vaxcyte Inc's reported EPS for the quarter was a loss of $1.80​.

• The company reported a quarterly loss of $246.51 million.

• Vaxcyte Inc shares had risen by 30.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 14.7% in the last three months.​

• In the last 30 days, ten analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Vaxcyte Inc is $110.00, about 45.2% above its last closing price of $60.26

This summary was machine generated from LSEG data February 24 at 10:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)